| 1 | 7537518 | Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. | Br J Cancer | 1995 May |
1 |
| 2 | 7565626 | Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. | Mol Pharmacol | 1995 Sep |
1 |
| 3 | 7595747 | Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. | J Clin Oncol | 1995 Nov |
2 |
| 4 | 8044293 | Column-switching high-performance liquid chromatographic method for the determination of a thymidylate synthase inhibitor, LY231514, an investigational agent for the treatment of solid tumors, in human plasma. | J Chromatogr B Biomed Appl | 1994 Apr 1 |
1 |
| 5 | 9067281 | LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. | Cancer Res | 1997 Mar 15 |
10 |
| 6 | 9533527 | A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. | Clin Cancer Res | 1998 Mar |
1 |
| 7 | 9717988 | Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. | Br J Cancer | 1998 |
4 |
| 8 | 9762351 | Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). | Adv Enzyme Regul | 1998 |
4 |
| 9 | 9858888 | Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. | Anticancer Res | 1998 Sep-Oct |
1 |
| 10 | 10226579 | Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. | Anticancer Res | 1999 Jan-Feb |
2 |
| 11 | 10545786 | Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. | Oncology | 1999 Oct |
1 |
| 12 | 10598557 | Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. | Semin Oncol | 1999 Apr |
2 |
| 13 | 10598560 | Overview of phase I trials of multitargeted antifolate (MTA, LY231514). | Semin Oncol | 1999 Apr |
2 |
| 14 | 10598563 | Overview of phase II trials of MTA in solid tumors. | Semin Oncol | 1999 Apr |
2 |
| 15 | 10732767 | Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. | Br J Cancer | 2000 Feb |
1 |
| 16 | 10847455 | Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. | Ann Oncol | 2000 Apr |
3 |
| 17 | 11252887 | Gemcitabine and Pemetrexed disodium in treating breast cancer. | Oncology (Williston Park) | 2001 Feb |
4 |
| 18 | 11384244 | Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. | J Med Chem | 2001 Jun 7 |
3 |
| 19 | 11417748 | Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. | Oncol Res | 2000 |
4 |
| 20 | 11524555 | Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. | Oncologist | 2001 |
1 |
| 21 | 11531245 | Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. | Br J Cancer | 2001 Sep 1 |
2 |
| 22 | 11742712 | Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. | Lung Cancer | 2001 Dec |
4 |
| 23 | 11763166 | Pemetrexed disodium (Eli Lilly). | Curr Opin Investig Drugs | 2001 Nov |
7 |
| 24 | 11848474 | Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells. | Anticancer Res | 2001 Sep-Oct |
1 |
| 25 | 12023790 | Pemetrexed for diffuse malignant pleural mesothelioma. | Semin Oncol | 2002 Apr |
1 |
| 26 | 12023791 | Pemetrexed: a promising new treatment for breast cancer. | Semin Oncol | 2002 Apr |
2 |
| 27 | 12023793 | Pemetrexed in the treatment of selected solid tumors. | Semin Oncol | 2002 Apr |
2 |
| 28 | 12023794 | Future directions in the development of pemetrexed. | Semin Oncol | 2002 Apr |
1 |
| 29 | 12094334 | Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). | Semin Oncol | 2002 Jun |
2 |
| 30 | 12094337 | Pemetrexed: translational research in breast cancer. | Semin Oncol | 2002 Jun |
2 |
| 31 | 12118332 | Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. | Int J Oncol | 2002 Aug |
2 |
| 32 | 12209673 | The pemetrexed/gemcitabine combination in pancreatic cancer. | Cancer | 2002 Aug 15 |
2 |
| 33 | 12437479 | Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. | Pharmacogenomics | 2002 Nov |
1 |
| 34 | 12450432 | Thymidylate synthase pharmacogenetics in colorectal cancer. | Clin Colorectal Cancer | 2001 Nov |
2 |
| 35 | 12571807 | Pemetrexed safety and dosing strategy. | Semin Oncol | 2002 Dec |
2 |
| 36 | 12571808 | Preclinical and clinical studies with combinations of pemetrexed and gemcitabine. | Semin Oncol | 2002 Dec |
2 |
| 37 | 12571811 | Pemetrexed in pancreatic cancer. | Semin Oncol | 2002 Dec |
2 |
| 38 | 12571812 | The role of pemetrexed in the treatment of colorectal cancer. | Semin Oncol | 2002 Dec |
1 |
| 39 | 12571813 | Pemetrexed: an active new agent for breast cancer. | Semin Oncol | 2002 Dec |
2 |
| 40 | 12663051 | Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. | Biochem Pharmacol | 2003 Apr 1 |
2 |
| 41 | 12720495 | Pemetrexed and its emerging role in the treatment of thoracic malignancies. | Expert Opin Investig Drugs | 2003 May |
1 |
| 42 | 12722017 | Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer. | Semin Oncol | 2003 Apr |
2 |
| 43 | 12860938 | Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. | J Clin Oncol | 2003 Jul 15 |
1 |
| 44 | 12907242 | Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. | Biochem Pharmacol | 2003 Aug 1 |
6 |
| 45 | 14596699 | The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. | Clin Lung Cancer | 2003 Jul |
2 |
| 46 | 14871988 | The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. | Clin Cancer Res | 2004 Feb 1 |
1 |
| 47 | 14981587 | Pemetrexed for treatment of advanced non-small cell lung cancer. | Semin Oncol | 2004 Feb |
1 |
| 48 | 15117425 | Pharmacology and mechanism of action of pemetrexed. | Clin Lung Cancer | 2004 Apr |
1 |
| 49 | 15117426 | Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma. | Clin Lung Cancer | 2004 Apr |
1 |
| 50 | 15117429 | Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed. | Clin Lung Cancer | 2004 Apr |
1 |